UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~September~~October 39, 2025

___________________________________________

NURIX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________


Delaware	001-39398	27-0838048
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)

1700 Owens Street, Suite 205 San Francisco, California		94158
(Address of Principal Executive Offices)		(Zip Code)

(415) 660-5320

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	NRIX	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 72.0102 ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition.

~~Nurix~~On ~~Therapeutics~~October 9, ~~Inc. (the “Company”) intends to conduct meetings with securities analysts~~2025, ~~investors~~Nurix ~~and others beginning on September 3~~Therapeutics, ~~2025~~Inc. ~~As part of these meetings~~, ~~the~~a ~~Company~~Delaware ~~intends~~corporation ~~to utilize an investor presentation~~ (the “~~Investor Presentation~~Company”), ~~which~~issued ~~includes~~a ~~updates~~press ~~about~~release announcing the Company’s ~~clinical~~financial ~~development~~results ~~plans~~ for ~~bexobrutideg~~the ~~(NX-5948),~~fiscal ~~its~~quarter ~~investigational~~ended ~~oral~~August 31, ~~brain-penetrant degrader of Bruton's tyrosine kinase, which is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies~~2025. The Apress ~~copy~~release ~~of the Investor Presentation~~ is ~~attached~~furnished ~~hereto~~ as Exhibit 99.1 and is incorporated herein by reference.

InThe ~~accordance~~information furnished with ~~General~~this ~~Instruction~~Item B.2 ~~of Form 8-K~~.02, ~~the~~including ~~information~~Exhibit ~~in Item 7~~99.011, ~~of this Current Report on Form 8-K~~ shall not be deemed ~~to be~~ “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the ~~liability~~liabilities of that section, ~~and~~nor shall ~~not~~it be deemed incorporated by reference ~~into~~in any ~~registration~~filing ~~statement or other document filed~~ under the Securities Act of 1933, as amended, or the Exchange Act, ~~except~~regardless asof ~~shall~~any begeneral ~~expressly~~incorporation ~~set~~language ~~forth by specific reference~~ in such filing. ~~In addition, the information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.~~

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

The following exhibits are filed herewith and this list is intended to constitute the exhibit index:


Exhibit No.						Exhibit Title or Description

99.1						Press Release dated October 9, 2025

104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

Exhibit No.						Exhibit Title or Description
99.1						Nurix Therapeutics, Inc. Investor Presentation dated September 3, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NURIX THERAPEUTICS, INC.
Date: September 3, 2025	By:	/s/ Christine Ring
Date: October 9, 2025	By:	/s/ Arthur T. Sands
		Christine Ring, Ph.D., J.D.
		Arthur T. Sands, M.D., Ph.D.
		Chief Legal Officer
		President and Chief Executive Officer

Filing Compare · Nurix Therapeutics, Inc.